Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

Inclusion Criteria

• •1. 18-75 years
• •2. Histologically confirmed MZL in untreated stage III or IV and needed for therapy as determined by the treating physician
• •3. ECOG performance status 0-2
• •4. Expected survival ≥ 6 months
• •5. Adequate hematologic and organ function: absolute neutrophil count ≥1,000/mm3 (independent of growth factor support), platelet counts ≥75,000/mm3, serum aspartate transaminase or alanine transaminase less than 2.5 times the upper limit of normal (ULN), serum creatinine ≤1.5×ULN, and bilirubin ≤1.5×ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of nonhepatic origin, in which case bilirubin should not exceed 3 g/dL, left ventricular ejection fraction (LVEF) of the heart≥ 50%
• •6. Women of childbearing potential and men who were sexually active were required to be practicing a highly effective method of birth control during and after the study
• •7. No history of other malignant tumors
• •8. At least one measurable lesion with a longest diameter of ≥ 1.5 cm or measurable lesions of extranodal lesions ≥ 1.0 cm.
• •9. Able to understand the study and provide signed Informed Consent Form